Hypersensitivity to vaccine including gelatin; neomycin. Blood dyscrasias, leukemia, lymphomas or other malignant neoplasms affecting bone marrow or lymphatic system. Immunosuppressive therapy eg, high-dose corticosteroids. Primary & acquired immunodeficiency states. Family history of congenital or hereditary immunodeficiency. Active untreated TB; active febrile illness w/ fever >38.5°C. Avoid pregnancy for 3 mth following vaccination.
Not to be inj intravascularly. Not to be given w/ Ig or varicella-zoster Ig. History of anaphylactic, anaphylactoid or other immediate reactions subsequent to egg ingestion. Family history of convulsions, history of cerebral injury or other condition in which stress due to fever should be avoided. HIV-infected w/ or w/o immunosuppression; thrombocytopenia; post-exposure prophylaxis. Avoid close association w/ high-risk individuals eg, immunocompromised, pregnant women & newborn infants w/o documented +ve history of varicella or lab evidence of prior infection for up to 6 wk following vaccination. Monitor temp elevation following vaccination. Temporary depression of tuberculin skin sensitivity. Avoid pregnancy for 3 mth following vaccination in women of childbearing potential. Not to be used during pregnancy. Lactation. Not recommended in infants <12 mth.
Fever ≥38.9°C, inj site erythema, pain/tenderness/soreness. Upper resp infection; irritability; diarrhea, vomiting; measles- & varicella-like rash, rash; inj site ecchymosis or swelling, rash.
Interfered immune response w/ Ig. Reye syndrome w/ salicylates; avoid use 6 wk after vaccination. Defer vaccination at least 3 mth following blood or plasma transfusions or Ig administration. Not to administer varicella-zoster Ig for 1 mth after administration. At least 1 mth should elapse between MMR vaccine & ProQuad; at least 3 mth should elapse between 2nd dose varicella-containing vaccine.